Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase III study analyzing the effectiveness of dalteparin therapy as intervention in recurrent pregnancy loss.

Next Previous
Trial Profile

Phase III study analyzing the effectiveness of dalteparin therapy as intervention in recurrent pregnancy loss.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 11 May 2015

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dalteparin sodium (Primary)
  • Indications Pregnancy complications; Spontaneous abortion; Thrombosis
  • Focus Therapeutic Use
  • Acronyms ETHIGII
  • Sponsors Pfizer

Most Recent Events

  • 16 Sep 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
  • 27 Jul 2007 The expected completion date for this trial is now 1 Jan 2011.
  • 24 Nov 2006 New trial record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top